416 Chemotherapy Flashcards
Chemotherapy agents
Antimetabolites Microtubule targeting agents Topoisomerase active agents Alkylating agents Miscellaneous agents
Antimetabolites
Cytarabine
Fluorouracil
Methotrexate
Class toxicities of antimetabolites
Myelosuppression
Diarrhea
Antimetabolite: Cytarabine DLT and HMT
DLT/HMT: cerebellar syndrome from high dose
Antimetabolite: Fluorouracil DLT and HMT
DLT/HMT: stomatitis and diarrhea
Enhances activity AND toxicity of 5FU
Leucovorin
Antimetabolite: Methotrexate DLT and HMT
DLT: myelosuppression, mucositis, diarrhea
HMT: myelosuppression, mucositis, diarrhea, nephrotoxicity
DDI with methotrexate
Bactrim
NSAID
PPI (?)
Given with MTX 24-36hrs pose dose
Leucovorin
-use with MTX doses >500
Drug used for MTX toxicity caused by renal toxicity
Glucarpidase
Microtubule-targeting agents
Paclitaxel
Docetaxel
Vincristine
Microtubule-targeting agents class SE
Peripheral neuropathy
Microtubule: Paclitaxel DLT and HMT
DLT: peripheral neuropathy
HMT: complete alopecia
Microtubule: Docetaxel DLT and HMT
HMT: edema
Microtubule: Vincristine DLT and HMT
DLT/HMT: peripheral neuropathy
Topoisomerase inhibitors
Doxorubicin
Irinotecan
Topoisomerase: Doxorubicin DLT and HMT
DLT/HMT: delayed cardiotoxicity (yrs after taking the agent)
Max accumulated dose: 450-550 mg/m2
Topoisomerase: Irinotecan DLT and HMT
DLT/HMT: delayed diarrhea (>12-24hrs post dose)
-loperamide 4mg at onset and 2mg q2h until resolution
Alkylating agents
Cyclophosphamide
Ifosfamide
Alkylating agents class SE
Sterility/infertility/teratogenic
Carcinogenic (leukemia, myelodysplastic syndrome)
Alkylating: Cyclophosphamide DLT and HMT
HMT: hemorrhagic cystitis
-trt with Mesna
Alkylating: Ifosfamide DLT and HMT
HMT: hemorrhagic cystitis
Platinum: Cisplatin and Carboplatin DLT and HMT
HMT: nausea, vomiting
Platinum: Oxaliplatin DLT and HMT
DLT/HMT: peripheral neuropathy
Anti-angiogenesis: Thalidomide DLT and HMT
HMT: teratogenicity
Corticosteroids
Prednisone
Dexamethasone
SE of corticosteroids
Insomnia, fluid retention, nausea, increased appetite, irritability, hyperglycemia
Immune therapies
PegIFN
IL-2
PegIFN SE
Flu-like symptoms
Neurologic toxicities
IL-2 SE
Hypotension, fluid retention, acute renal dysfunction
GI hemorrhage, stomatitis
Capillary leak syndrome (high dose)
Targeted therapy agents
Histone deacetylase inhibitors
PARP inhibitors
Proteasome inhibitors
Histone: Panobinostat DLT and HMT
HMT: QT prolongation
PARP: Olparib SE
Anemia, nausea, increased SCr, AML/MDS
Proteasome: Bortezomib DLT and HMT
DLT/HMT: peripheral neuropathy
